All In Biotech

NDA 021602 · Takeda Pharms USA

Velcade

Bortezomib · Intravenous, Subcutaneous · Proteasome Inhibitor

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 4, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

May 13, 2003

Approved uses

13

Original approval plus efficacy supplements

Registered trials

1,027

156 Phase 3, 82 recruiting

FAERS reports

89,988

75,667 serious, 14,182 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 28, 2025.

VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma.

Mechanism: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VELCADE · BORTEZOMIB 3.5MG/VIAL · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bortezomib" as an intervention, any sponsor and status, largest first.

All 1,027 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma9,241
  • neuropathy peripheral6,529
  • off label use6,498
  • diarrhoea5,237
  • fatigue4,581
  • death4,220
  • pneumonia4,108
  • drug ineffective3,816
  • thrombocytopenia3,761
  • nausea3,129
  • pyrexia2,898
  • neutropenia2,749

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004486
2005906
2006949
2007930
20081,285
20091,463
20101,604
20112,045
20123,007
20132,560
20142,551
20158,052
20164,697
20174,756
20185,415
20196,400
20207,052
20217,529
20227,188
20236,712
20245,857
20254,910
20263,634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Velcade (Bortezomib)

2024 spending

$670K

Beneficiaries

36

175 claims

Per beneficiary

$18,609

$1,515.66 per unit

View as table
YearSpending
2020$14,973,142
2021$12,145,291
2022$7,664,156
2023$1,878,202
2024$669,923

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,311 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.